Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | POLA1 | P09884 | 1/20 | 0.38 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26653694 | 1.00 | NPC1L1 (0.51) | NPC1L1USP2LMNAMAPTALDH1A1 | |
| SCHEMBL26783736 | 1.00 | NPC1L1 (0.51) | NPC1L1USP2LMNAMAPTALDH1A1 | |
| SCHEMBL26783733 | 1.00 | NPC1L1 (0.51) | NPC1L1USP2LMNAMAPTALDH1A1 | |
| SCHEMBL26653373 | 0.90 | NPC1L1 (0.49) | NPC1L1USP2LMNAMAPTALDH1A1 | |
| SCHEMBL26653376 | 0.90 | NPC1L1 (0.49) | NPC1L1USP2LMNAMAPTALDH1A1 | |
| SCHEMBL29486954 | 0.90 | NPC1L1 (0.49) | NPC1L1USP2LMNAMAPTALDH1A1 | |
| SCHEMBL26783767 | 0.89 | NPC1L1 (0.51) | NPC1L1USP2LMNAMAPTALDH1A1 | |
| SCHEMBL26785093 | 0.89 | NPC1L1 (0.51) | NPC1L1USP2LMNAMAPTALDH1A1 | |
| SCHEMBL24358400 | 0.88 | NPC1L1 (0.52) | NPC1L1USP2LMNAMAPTALDH1A1 | |
| SCHEMBL26783716 | 0.88 | NPC1L1 (0.52) | NPC1L1USP2LMNAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365616-A1 | CHOLESTANE DERIVATIVES, PREPARATIONS CONTAINING THESE DERIVATIVES AND USE THEREOF | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2023-11-16 | — | — | US | disclosed |
| WO-2022083809-A1 | CHOLESTANE DERIVATIVES, PREPARATIONS CONTAINING THESE DERIVATIVES AND USE THEREOF | Univerzita Palackého v Olomouci (CZ) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365616-A1 | CHOLESTANE DERIVATIVES, PREPARATIONS CONTAINING THESE DERIVATIVES AND USE THEREOF | BAD, CYP27A1, NPC1L1 | NPC1L1 3/4885USP2 2187/4885LMNA 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.